title: Strontium-89 therapy for painful osseous metastatic prostate and breast cancer.
abstract: Strontium-89 chloride is a radiopharmaceutical that localizes to actively forming new bone, such as metastatic bone lesions from prostate and breast cancer. It provides effective systemic endo-osseous local radiation therapy to these painful lesions. Strontium-89 will soon be available to physicians in the United States for use in the palliative management of metastatic bone pain.
authors.affiliation: Sacred Heart Medical Center, Spokane, Washington.
authors.forename: D V
authors.initials: DV
authors.lastname: Hansen
authors.forename: E R
authors.initials: ER
authors.lastname: Holmes
authors.forename: G
authors.initials: G
authors.lastname: Catton
authors.forename: D A
authors.initials: DA
authors.lastname: Thorne
authors.forename: D H
authors.initials: DH
authors.lastname: Chadwick
authors.forename: D A
authors.initials: DA
authors.lastname: Schmutz
mesh_terms: D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology*; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D006801:Humans; D008297:Male; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000473:pathology*; D013326:Strontium Radioisotopes / Q000627:therapeutic use*
chemical_list: D013326:Strontium Radioisotopes